Novo wins EU nod for Wegovy pill and higher-dose Wegovy in single-dose pen

EU approval is crucial to NVO's global growth strategy, particularly with the launch of the oral Wegovy, which enhances drug accessibility and patient convenience. The EU market accounts for approximately 20% of global sales, and the approval is expected to serve as a positive signal for further market expansion (in the U.S., Japan, etc.). While the financial burden is minimal, there are expectations for long-term profitability improvement through increased market share.

Over the past three months, stable support has been confirmed in the $680-$700 range. If the upward trend continues, there is a high possibility of breaking through $720, and it is considered a short-term accumulation phase. However, if a correction occurs alongside an overbought signal (RSI 70+), it can be utilized as a re-entry opportunity in the $660-$670 range.

The EU approval accelerates the launch of Wegovy's oral and high-dose pen, strengthening its competitive advantage in the diabetes and obesity treatment market. In particular, the obesity treatment market is expected to grow at a CAGR of 15% by 2030, increasing the likelihood of NVO leading the market due to its pipeline competitiveness and synergistic effects. Additionally, the likelihood of U.S. FDA approval is also increasing, raising expectations for a chain reaction of global regulatory approvals.